Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
The U.S. Food and Drug Administration said that 17 serious adverse events, including two that resulted in death, have been reported in worldwide recipients of the vaccine Ixchiq over the age of 60. Six of the events occurred in the United States, the FDA said in a safety communication on Monday, May 12.
Domestic and global cases have been reported to the Vaccine Adverse Event Reporting System, run by the FDA and the U.S. Centers for Disease Control to flag potential safety problems with vaccines. The reported cases were in individuals with underlying chronic medical conditions and the adverse events "may not be causally related to vaccination," the FDA said.
The vaccine's maker, Valneva, said in a statement that it is "upholding the highest safety standards" and pointed to the potential for underlying conditions and other medications as contributing factors in the adverse events.
"Thorough evaluation of these cases is critical to ensure the safe use of Ixchiq," the company said.
French drug regulators updated their recommendations for Ixchiq in April and the European Medicines Agency announced that its safety committee had launched a review of the vaccine earlier this month and prohibited its use in people 65 and older, according to the Center for Infectious Disease Research and Policy at the University of Minnesota.
Chikungunya is a mosquito-borne illness named for the joint pain it causes, according to the Cleveland Clinic.
Most people infected by a mosquito bite recover from the illness in about one week, but some have lasting joint pain – the clinic says. There is no cure for the disease and treatment focuses on managing symptoms inlcuding:
Headache
Muscle pain
Swelling in joints
Rash
Fatigue
Nausea
The FDA approved Ixchiq for the prevention of the disease in adults over 18 in November 2023. It uses a live, though weakened, version of the virus that may cause symptoms similar to the disease, according to the FDA.
The FDA said that some of the reported adverse events were consistent with severe complications of chikungunya disease.
The FDA said it will conduct an updated benefit-risk assessment for the use of Ixchiq in the 60-and-up age bracket and that both the agency and the CDC will continue monitoring safety reports for the vaccine.
This article originally appeared on USA TODAY: Feds recommend pause for chikungunya vaccine in people over 60
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
32 minutes ago
- Medscape
Allergy Med Dilemma: Is Drug Working? Still Needed?
A new allergy medication is prompting clinicians to adjust their approach to oral food challenges — medically supervised tests in which clinicians give increasing doses of an allergen like peanut or milk to see how a patient reacts. The FDA in 2024 approved omalizumab (Xolair) to help reduce allergic reactions in adults and children aged 1 year or older with immunoglobulin E-mediated food allergy. Patients receiving the injections are supposed to avoid foods to which they are allergic. In the event of an accidental exposure, the medication can afford protection against a serious reaction. The approval opened a new frontier in allergy therapy but also raised questions without clear answers, like: How can patients be sure the medication is working? And how will they know if they 'outgrow' an allergy, as some people do? After the approval, clinicians wrote to the American Academy of Allergy, Asthma & Immunology seeking advice. Earlier this year, a committee for the academy published a report with 'consensus-based guidance' on using omalizumab for food allergy and acknowledged that clinical guidance will likely evolve as groups monitor and report real-world outcomes. In the meantime, the committee suggested that various approaches to treatment, including the use of oral food challenges to assess treatment response, could be used. 'Clinicians should consider assessing treatment success against individualized goals that the patient and prescribing clinician have set for therapy,' they wrote. Any food challenges 'to assess treatment response should be offered no earlier than 16-20 weeks after initiating omalizumab therapy,' the duration of treatment in a randomized trial that supported the drug's approval for food allergy, they wrote. 'In nonresponding patients, the clinician should strongly consider discontinuation of omalizumab given lack of benefit.' Although its use for food allergy is relatively new, omalizumab is not a new medication. The drug first was approved for asthma in 2003. The drug also is approved to treat chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps. 'Bite Safe' Testing? Scott Sicherer, MD, director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai in New York City, fielded the inquiry when a clinician wrote to the American Academy of Allergy, Asthma, & Immunology's 'Ask the Expert' column last year wondering: 'With recent approval of Xolair for management of food allergies, how do we approach food challenges?' In some cases, additional food challenges make sense before starting omalizumab to confirm or rule out possible allergies, so patients are not avoiding certain foods unnecessarily while on therapy, responded Sicherer, who coauthored a 2024 paper in The New England Journal of Medicine about omalizumab for the treatment of multiple food allergies. After starting therapy, a scaled back food challenge to determine whether treatment has rendered an allergen 'bite safe' might be reasonable, added Sicherer, meaning a patient could accidentally have a bite of the food in question without a severe reaction. 'Given that the commitment to treatment includes time and expense and there are no good biomarkers yet, and a small percentage of people do not respond, I think many patients would like an [oral food challenge] to some agreed upon amount of the food, perhaps something they would view as 'bite safe,'' Sicherer wrote in his response. 'If the treatment is not protecting them to small amounts, why continue?' The exact parameters of such a test could depend on the patient's goals, Sicherer told Medscape Medical News . Some patients might simply look for reassurance that they could eat half a peanut without a problem. If that is the case, 'maybe that is what we would aim for,' Sicherer said. 'It's not like there is a rule written down about this.' Introducing Egg Sicherer's reply also discussed ways to handle a scenario where a patient on omalizumab had egg, cashew, and peanut allergies — with the egg allergy expected to resolve. One approach could involve discontinuing omalizumab for at least 4-5 months before performing an oral food challenge with egg, he wrote. Alternatively, clinicians might conduct a food challenge with egg while the patient remains on omalizumab. If they tolerate the full amount of egg on therapy, they could be encouraged to eat that food regularly, Sicherer said. Then if the patient eventually stops omalizumab and has symptoms after eating egg, then perhaps the allergy never resolved, he added. Shared Decisions Understanding a family's goals and preferences is crucial, said Jennifer Dantzer, MD, assistant professor of pediatrics in the Division of Allergy, Immunology, and Rheumatology at Johns Hopkins University School of Medicine in Baltimore. Decisions about food challenges for patients on omalizumab is 'something that we are talking through with every family,' said Dantzer, who has studied the medication and coauthored the article in The New England Journal of Medicine with Sicherer. The definition of treatment success can vary. In some cases, a child might be able to consume a full serving of an allergen. Or a patient might react to a relatively small amount but have a reaction that is far less severe than before. Either instance could be deemed a success. Results from food challenges can provide reassurance that certain activities like dining out are now lower risk, Dantzer said. For now, clinicians have no firm guidelines about when to reassess therapy or consider adjusting the dose. 'I think the allergy community would like there to be a bit more guidance,' Dantzer said. 'Hopefully with time that will become available.'
Bloomberg
33 minutes ago
- Bloomberg
FDA's Push for 'Radical Transparency'
Wall Street Week FDA Commissioner Martin Makary says the agency will begin publishing drug rejection letters—long kept confidential—to help developers better understand what he calls the FDA's 'black box.' (Source: Bloomberg)
Business Wire
an hour ago
- Business Wire
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccination is the first and most important action recommended to reduce the risk of flu and its potentially serious outcomes. Ideally, vaccination should occur by the end of October, but people can continue to get vaccinated as long as the flu poses a threat. 1 CDC recommends an annual flu vaccination for anyone aged six months or older who does not have contraindications. 1,2 CDC estimates that from October 1, 2024, through May 17, 2025, there were 47 – 82 million flu illnesses, 610,000 – 1.3 million flu hospitalizations and 27,000 – 130,000 flu deaths. 3 The 2024-25 flu season was the first season since 2017-18 that the CDC classified as high severity, and preliminary CDC estimates indicate that it was the worst flu season (based on flu illnesses, hospitalizations and deaths) the US has seen in the last 15 years. 4,5 For egg-based influenza vaccines for the 2025-26 flu season in the Northern Hemisphere, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended including an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Croatia/10136RV/2023 (H3N2)-like virus and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. 6 About Influenza The flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and sometimes the lungs. It can cause mild-to-severe illness and at times can lead to death. 7 Anyone, including healthy people, can get the flu, however, it can be more serious for children younger than five, adults 65 years and older, people with a body mass index (BMI) of 40 kg/m 2 or higher, pregnant women and people with pre-existing chronic health conditions, such as asthma, diabetes and heart disease. 7 For more information about the flu, visit Indication for FLUARIX and FLULAVAL FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older. Important Safety Information for FLUARIX and FLULAVAL Do not administer FLUARIX or FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX or FLULAVAL should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX and FLULAVAL. Procedures should be in place to avoid injury from fainting. Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUARIX and FLULAVAL. If FLUARIX or FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons. The most common solicited local adverse reactions with FLUARIX in adults were pain and redness, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 5 through 17 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 3 through 4 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children aged 6 through 35 months who received FLUARIX QUADRIVALENT, the most common solicited local adverse reactions were pain and redness, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. The most common solicited local adverse reactions with FLULAVAL in adults were pain, redness, and swelling, and the most common solicited systemic adverse reactions were fatigue, headache, and muscle aches/arthralgia. In children aged 3 through 17 years, the most common solicited local adverse reaction was pain. In children aged 3 through 4 years, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children aged 5 through 17 years, the most common solicited systemic adverse reactions were muscle aches, headache, and fatigue. In children aged 6 through 35 months who received FLULAVAL QUADRIVALENT, the most common solicited local adverse reaction was pain, and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. Vaccination with FLUARIX or FLULAVAL may not result in protection of all vaccine recipients. Please see full Prescribing Information for FLUARIX and for FLULAVAL. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in GSK's Annual Report on Form 20-F for 2024. Registered in England & Wales: No. 3888792 References
